First clinical experience with single-photon emission computed tomography with technetium-99m-labeled prostate-specific membrane antigen at the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine

Aniskova A.Yu., Afanas’eva N.G.

Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, Chelyabinsk, Russia

Background: Positron emission tomography combined with computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-based radiopharmaceuticals is widely used in the management of patients with prostate cancer. However, this method may be unavailable in some regions due to the lack of a positron emission tomography (PET) scanner. Therefore, a new method may be used: single-photon emission computed tomography combined with computed tomography (SPECT/CT) using technetium-99m-labeled PSMA (^99mTc-PSMA).
Objective: Evaluation of the clinical application of SPECT-CT with ^99mTc-PSMA in patients with prostate cancer.
Materials and methods: The study was conducted at the Department of Radionuclide Diagnostics, Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine. The study included four patients with prostate cancer, aged 55–80 years, with biochemical recurrence: prostate-specific antigen (PSA) 16.2 ng/ml, PSA 50.58 ng/ml, PSA 4.24 ng/ml, and PSA 17.2 ng/ml. All patients underwent planar imaging followed by SPECT/CT of the region of interest.
Results: The study results indicate that this method is informative in visualizing local recurrences and/or metastases, and can also be used to assess the extent of the disease.
Conclusion: SPECT/CT with 99mTc-PSMA in patients with biochemical recurrence revealed tumor invasion into surrounding tissue in two patients and metastatic disease in all subjects.

For citations: Aniskova A.Yu., Afanas’eva N.G. First clinical experience with single-photon emission computed tomography with technetium-99m-labeled prostate-specific membrane antigen at the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine. Pharmateca. 2026;33(4):222-228. (In Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2026.4.222-228

Authors’ contribution: Concept and design of the study – Aniskova A.Yu. Collection and processing of materials – Aniskova A.Yu., Afanas’eva N.G. Statistical processing – Aniskova A.Yu. Writing the text – Aniskova A.Yu. Editing – Aniskova A.Yu., N.G. Afanas’eva. Compilation of the list of references – Aniskova A.Yu., N.G. Afanas’eva.
Conflicts of interest: The authors confirm that they have no conflicts of interest to declare.
Funding: The study was conducted without any sponsorship.
Ethical Approval: The study was approved by the Ethics Committee of the Chelyabinsk Regional Center for Oncology and Nuclear Medicine. See extract from minutes No. 5 of the Ethics Committee meeting dated April 10, 2024.
Patient Consent for Publication: All patients provided informed consent for the publication of their data.
Authors’ Data Sharing Statement: The data supporting the findings of this study are available upon request from the corresponding author after approval from the principal investigator.

Keywords

About the Authors

Anastasia Yu. Aniskova, Radiologist, Department of Radionuclide Diagnostics, Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, Chelyabinsk, Russia; mau8aaa@mail.ru, ORCID: https://orcid.org/0009-0004-7285-6040 (corresponding author)
N.G. Afanas’eva, Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, Chelyabinsk, Russia; ORCID:
https://orcid.org/0000-0002-9432-5396

Similar Articles